From Name

From Email

To Name

To Email

Message

Stent Platform Now Indicated for Patients With High Bleeding Risk

from Healio

Stent Platform Now Indicated for Patients With High Bleeding Risk Healio Boston Scientific announced that its bioabsorbable polymer stent platform has received a new indication from the FDA to treat patients at high bleeding risk. This stent platform (Synergy), which is the only system approved for this indication in the U.S., was designed to allow a shorter duration of dual antiplatelet therapy for patients at high bleeding risk, according to an email from the company. READ MORE

more